Parecoxib, the only non-enteric administered COX-2 inhibitor among NSAIDs, is able to inhibit epithelial-mesenchymal transition and metastasis of human CRC cells by down-regulation of β-conjugated proteins, and inhibit CRC metastasis in combination with chemotherapeutic agents 130. This evidence concerns the gene PTGS2 and colorectal carcinoma.